Blue Light Cystoscopy with Cysview utilizes a special scope and dye to detect and treat non muscle invasive bladder cancer.

In the 10-Q report, CG Oncology reported a net loss of $34.5 million for the three months ended March 31, 2025, compared to a ...

Immune checkpoint inhibitors have shown a survival benefit in patients with metastatic urothelial cancer, so investigators trialed neoadjuvant nivolumab and ipilimumab in patients with muscle-invasive ...

Q1 2025 Earnings Call Transcript May 12, 2025 UroGen Pharma Ltd. misses on earnings expectations. Reported EPS is $-0.92 EPS, ...

The trial was conducted across over 120 centres in 12 nations, including Canada, and regions across Asia and Europe.

Durvalumab plus full BCG significantly improved disease-free survival in high-risk early bladder cancer vs BCG alone in the ...

Imfinzi plus BCG induction and maintenance therapy showed a statistically and clinically meaningful improvement in DFS for ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of non-muscle | ...

"The positive results for Imfinzi in the Potomac trial represent a significant advance that will potentially allow more patients with early-stage bladder cancer to benefit from this important ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

UroGen Pharma ( NASDAQ: URGN) announced on Wednesday that the U.S. FDA has scheduled an Oncologic Drugs Advisory Committee ...

ImmunityBio's sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a ...